Rami Galal
Overview
Explore the profile of Rami Galal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
282
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kluth M, Amschler N, Galal R, Moller-Koop C, Barrow P, Tsourlakis M, et al.
Oncotarget
. 2016 Nov;
8(1):379-392.
PMID: 27880722
Deletion of chromosome 8p is the second most frequent genomic alteration in prostate cancer. To better understand its clinical significance, 8p deletion was analyzed by fluorescence in-situ hybridization on a...
2.
Talaat M, Saied T, Kandeel A, El-Ata G, El-Kholy A, Hafez S, et al.
Antibiotics (Basel)
. 2016 Mar;
3(3):450-60.
PMID: 27025755
Inappropriate antibiotic use leads to increased risk of antibiotic resistance and other adverse outcomes. The objectives of the study were to determine the prevalence and characteristics of antibiotic use in...
3.
Kluth M, Galal R, Krohn A, Weischenfeldt J, Tsourlakis C, Paustian L, et al.
Int J Oncol
. 2015 Jan;
46(4):1637-42.
PMID: 25625310
Prostate cancer is characterized by structural rearrangements, most frequently including translocations between androgen-dependent genes and members of the ETS family of transcription factor like TMPRSS2:ERG. In a recent whole genome...
4.
Kluth M, Harasimowicz S, Burkhardt L, Grupp K, Krohn A, Prien K, et al.
Int J Cancer
. 2014 Feb;
135(6):1369-80.
PMID: 24523142
Despite a multitude of p53 immunohistochemistry (IHC) studies, data on the combined effect of nuclear p53 protein accumulation and TP53 genomic inactivation are lacking for prostate cancer. A tissue microarray...
5.
Weischenfeldt J, Simon R, Feuerbach L, Schlangen K, Weichenhan D, Minner S, et al.
Cancer Cell
. 2013 Feb;
23(2):159-70.
PMID: 23410972
Early-onset prostate cancer (EO-PCA) represents the earliest clinical manifestation of prostate cancer. To compare the genomic alteration landscapes of EO-PCA with "classical" (elderly-onset) PCA, we performed deep sequencing-based genomics analyses...